Objective  To evaluate the efficacy， safety， stability and predictability of the Verisyse phakic iris-fixated intraocular lens （PIOL） for the correction of severe myopia. Methods  In this prospective cohort study， 37 patients （65 eyes）， aged from 17 to 44 years with severe myopia of -9.00- -27.00 D（-18.55±4.19 D）， were implanted with Verisyse phakic iris-fixated intraocular lenses from June 2005 to March 2012. Visual acuity， refraction， intraocular pressure， corneal endothelium， Verisyse IOL position， contrast sensitivity， glare sensitivity， surgical complications and poor visual symptoms were observed on 1 day， 1 week， 1 month， 3 months， 6 months， 1 year， 2 years， 3 years， and 5 years. Then safety index and efficacy index were obtained from BSCVA and UCVA. Results  The mean safety index and efficacy index were better than 1 at most times except at 1 month and 24 months. At 5 years， the mean manifest refraction was within 1 D of the attempted correction in 93% of eyes and within 0.5 D of the attempted correction in 84% of eyes. Near vision and intraocular pressure were not significantly different at 5 years. The mean loss of corneal endothelium was 3.0%±2.5%（0.07%-9.1%）. The distance from the corneal endothelium to the PIOL was 2.20±0.15 mm（>2 mm） and 0.73±0.08 mm（>0.5 mm） from the PIOL to the natural lens. There were statistically significant differences between preoperative and postoperative contrast sensitivity and glare sensitivity. Postoperative complications included 2 eyes with light inflammatory deposits on the PIOL surface， 1 eye with an oval pupil and 1 patient （2 eyes） with dislocated PIOLs. More than 80% of eyes had depigmented irises at the attachment sites. Conclusion  Verisyse IOL implantation for the correction of severe myopia is effective， safe， stable and predictable. It can be a supplement for corneal refractive surgery but follow-up is still required for the evaluation of long-term results.